Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum

International Journal of Radiation Biology

Volumn 81, Issue 12, 2005, Pages 937-944

  Lukacova, Slavka ^a   Khalil, Azza A ^a   Overgaard, Jens ^a   Alsner, Jan ^a   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

C3H mouse mammary carcinoma; Osteopontin; Radiobiological hypoxia; Serum tumour marker

Indexed keywords

BIOCHEMICAL MARKER; OSTEOPONTIN; TUMOR MARKER;

ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPOXIA; HYPOXIC CELL; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RADIOBIOLOGY; REOXYGENATION; TARGET CELL; TISSUE SECTION; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA; CELL HYPOXIA; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; NECROSIS; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; SIALOGLYCOPROTEINS;

ANIMALIA;

EID: 33644845897     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000600567616     Document Type: Article

References (30)

1. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research 56:941-943.
2. Brizel DM, Sibley GS, Prosnitz LR, Scher R, Dewhirst MW. 1997. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics 38:285-289.
3. Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Research 58:1408-1416.
4. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ. 2004. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clinical Cancer Research 10:184-190.
5. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ. 2003. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914.
6. Ehrnrooth E, von der MH, Sorensen BS, Poulsen JH, Horsman MR. 1999. The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo. International Journal of Radiation Biology 75:885-889.
7. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. 1953. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British Journal of Radiology 26:638-648.
8. Harris AL. 2002. Hypoxia - a key regulatory factor in tumour growth. Nature Reviews. Cancer 2:38-47.
9. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56:4509-4515.
10. Hockel M, Vaupel P. 2001. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93:266-276.
11. Horsman MR. 1998. Measurement of tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics 42:701-704.
12. Horsman MR, Chaplin DJ, Overgaard J. 1990. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Research 50:7430-7436.
13. Horsman MR, Khalil AA, Nordsmark M, Grau C, Overgaard J. 1993. Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiotherapy and Oncology 28:69-71.
14. Horsman MR, Overgaard J. 2002. Overcoming tumour radio-resistance resulting from hypoxia. In Steel GG, editor. Basic clinical radiobiology, editor. London: Arnold. pp 169-191.
15. Kallinowski F, Zander R, Hoeckel M, Vaupel P. 1990. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. International Journal of Radiation Oncology, Biology, Physics 19:953-961.
16. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ. 2003. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clinical Cancer Research 9:59-67.
17. Moulder JE, Rockwell S. 1984. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. International Journal of Radiation Oncology, Biology, Physics 10:695-712.
18. Nordsmark M, Alsner J, Eriksen JG, Horsman MR, Overgaard J. 2003. The prognostic value of serum osteopontin, HIF-1 alpha and pO2 measurements in advanced head and neck tumors treated by radiotherapy. European Journal of Cancer 1:S145.
19. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, Overgaard J. 2001. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. The British Journal of Cancer 84:1070-1075.
20. Nordsmark M, Overgaard M, Overgaard J. 1996. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 41:31-39.
21. Overgaard J. 1980. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. International Journal of Radiation Oncology, Biology, Physics 6:1507-1517.
22. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. 2005. Plasma osteopontin predicts hypoxia and response to the hypoxic sensitizer Nimorazole in radiotherapy of head and neck cancer. Results from the randomized DAHANCA 5 trial. Lancet Oncology 6:757-764.
23. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K. 1998. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology 46:135-146.
24. Said HM, Katzer A, Flentje M, Vordermark D. 2005. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiotherapy and Oncology 76:200-205.
25. Semenza GL. 2000. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochemical Pharmacology 59:47-53.
26. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. 1988. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Research 48:5770-5774.
27. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. 1997. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research 3:605-611.
28. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, Horsman MR. 2005. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiotherapy and Oncology 76:187-193.
29. Vaupel P, Kallinowski F, Okunieff P. 1989. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Research 49:6449-6465.
30. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le QT. 2005. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555-6563.